Comorbid conditions - a reason to strengthen antianginai therapy in patients with stable coronary artery disease
https://doi.org/10.33667/2078-5631-2021-23-49-52
Abstract
In the article on the example of a clinical case approaches to enhancing antianginal therapy of coronary artery disease were discussed. Arguments were given for prescribing preparations of the second line of antianginal agents (thymetazidine) in the patient with stable angina with high functional class and concomitant hypotonia after a complicated COVID-19. The main mechanisms of action of trimetazidine and results of clinical studies were discussed.
Keywords
Supporting agencies: The article was prepared with the informational support of the company CJSC «Canonpharma Production». The development of approaches to optimizing the treatment of patients with chronic ischemic heart disease is carried out within the framework of the fundamental theme of the Research Institute for Complex Issues of Cardiovascular Diseases "Multifocal atherosclerosis and comorbid conditions. Features of diagnostics, risk management in a large industrial region of Siberia «and with information support from the World-class Scientific and Educational Center «Kuzbass»
About the Authors
O. L. Barbarash
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation
Russian Federation
Olga L. Barbarash, DM Sci, Professor, Corresponding Member of the Russian Academy of Sciences, Director; head of cardiology and cardiovascular surgery chair
Kemerovo
V. V. Kashtalap
Research Institute for Complex Issues of Cardiovascular Diseases; Kemerovo State Medical University
Russian Federation
Russian Federation
Vasily V. Kashtalap, DM Sci, Professor Associate, Head of the Department of Clinical Cardiology, professor of cardiology and cardiovascular surgery chair
Kemerovo
References
1. Federal State Statistics Service Russian Federation. Available at: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/en/main/ (accessed: 07.08.2021).
2. Барбараш О. Л., Каретникова В. Н., Кашталап В. В., Зверева Т. Н., Кочергина А. М. Новая коронавирусная болезнь (COVD-19) и сердечно-сосудистые заболевания. Комплексные проблемы сердечно-сосудистых заболеваний. 2020;9(2):17-28. [Barbarash O. L., Karetnikova V. N., Kashtalap V. V., Zvereva T. N., Kochergina A. M. New coronavirus disease (COVD-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases. 2c20;9(2)I7-28. (in Russ.)] DOI: 10.17802/2306-1278-2020-9-2-17-28
3. Белялов Ф. И. Особенности диагностики и лечения ишемической болезни сердца у пациентов пожилого и старческого возраста. Российский кардиологический журнал. 2017;3:72-76. [Belyalov F. I. The specifics of ischemic heart disease management in elderly. Russian Journal of Cardiology. 2017;3:72-76. (In Russ.)] DOI: 10.15829/1560-4071-2017-3-72-76.
4. Стабильная ишемическая болезнь сердца. Клинические рекомендации - 2020. Российский кардиологический журнал. 2020;25(11):4076. [Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(ll):4076. (In Russ.)] DOI: 10.15829/1560-4071-2020-4076.
5. ISCHEMIA Trial Research Group, Maron D. J., Hochman J. S., O’Brien S. M., Reynolds H. R., Boden W. E., Stone G. W., Bangalore S., Spertus J. A, Mark D. B., Alexander K. P, Shaw L., Berger J. S., Ferguson T. B. Jr, Williams D. O. , Harrington R. A., Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 Jul; 201:124-135. DOI: I0.l0l6/j.ahj.20l8.04.0ll.
6. Kantor P. F., Lucien A., Kozak R., Lopaschuk G. D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86(5):580-8. DOI: I0.ll6l/0l.res.86.5.580.
7. El Banani H., Bernard M., Baetz D. et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischemia. Cardiovasc Res. 2000;47(4):688-96. DOI: I0 .I0 I6 /s0008-6363(00)00I36-x.
8. Marzilli M., Klein W. W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003;І4(2):І7І-9. DOI: 10.1097/00019501-200304000-00010.
9. Peng S., Zhao M., Wan J. et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 20l4;l77(3):780-5. DOI: I0.l0l6/j.ijcard.20l4.l0.l49.
10. Szwed H., Sadowski Z., Elikowski W. et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J. 2001;22(24):2267-74. DOI: I0.l053/euhj.200l.2896.
11. Sellier P., Audouin P., Payen B. et al. Acute effects of trimetazidine evaluated by exercise testing. Eur J Clin Pharmacol. 1987;33(2):205-7. DOI: 10.1007/BF00544569.
12. Марцевич С. Ю., Кутишенко Н. П., Гинзбург М. Л. и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. РФК. 2012;8(2):179-84. [Martsevich S. Yu., Kutishenko N. P., Ginzburg M. L. et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacother. Card. 2012;8(2):179-84. (In Russ.)]
13. Барбараш О.Л., Кашталап В. В., Кривошапова К. Е. Пациент с ишемической болезнью сердца пожилого возраста. Какие вопросы предстоит решить? Медицинский алфавит. 2021;(11):8-11. [Barbarash O. L., Kashtalap V. V., Krivoshapova K. E. Elderly patient with coronary artery disease. What are common problems that need solving? Medical alphabet. 2021;(11):8-11 (in Russ). DOI: https://doi.org/10.33667/2078-5631-2021-11-8-11.
Review
For citations:
Barbarash O.L., Kashtalap V.V. Comorbid conditions - a reason to strengthen antianginai therapy in patients with stable coronary artery disease. Medical alphabet. 2021;(23):49-52. (In Russ.) https://doi.org/10.33667/2078-5631-2021-23-49-52
Views:
296
Email this article 